Prognostic impact of C-reactive protein-albumin ratio for the lethality in castration-resistant prostate cancer

Taizo Uchimoto, Kazumasa Komura, Yuya Fujiwara, Kenkichi Saito, Naoki Tanda, Tomohisa Matsunaga, Atsushi Ichihashi, Takeshi Tsutsumi, Takuya Tsujino, Yuki Yoshikawa, Yudai Nishimoto, Tomoaki Takai, Koichiro Minami, Kohei Taniguchi, Tomohito Tanaka, Hirofumi Uehara, Hajime Hirano, Hayahito Nomi, Naokazu Ibuki, Kiyoshi TakaharaTeruo Inamoto, Haruhito Azuma

Research output: Contribution to journalArticle

Abstract

This study aimed to assess the clinical value of C-reactive protein-albumin ratio (CAR) at the initiation of first-line treatment for castration-resistant prostate cancer (CRPC). We identified 221 CRPC patients treated with either androgen-signaling inhibitors (ASIs: abiraterone and enzalutamide) or docetaxel as the first-line treatment. The value of CAR was evaluated at the initiation of first-line treatment. The optimal cutoff value of CAR for the prediction of lethality was defined by the receiver operating characteristic curve and the Youden Index. The primary endpoints of the study included overall survival (OS) and cancer-specific survival (CSS). The median age was 74 years. The optimal cutoff value of CAR in newly diagnosed CRPC patients was 0.5 (CAR > 0.5: n = 77 and CAR ≤ 0.5: n = 144). The 3-year OS and CSS rate in patients with CAR > 0.5 were significantly lower than those with CAR ≤ 0.5 (OS: 30.9% vs 55.5%, p < 0.001) (CSS: 42.5% vs 65.4%, p < 0.001). A multivariate analysis consistently demonstrated that CAR was an independent predictor for both OS and CSS. When stratified by the first-line treatments, patients with CAR > 0.5 has significantly shorter CSS than those with CAR ≤ 0.5 in abiraterone (median of 23 vs 49 months, p < 0.001) and enzalutamide (median of 23 vs 41 months, p = 0.0016), whereas no difference was observed in patients treated with docetaxel as the first-line treatment (median of 34 and 37 months, p = 0.7708). Despite the limited cohort size and retrospective design, increased CAR seemed to serve as an independent predictor of OS and CSS for patients newly diagnosed with CRPC.

Original languageEnglish
Article number9
JournalMedical Oncology
Volume37
Issue number1
DOIs
Publication statusPublished - 01-01-2020

Fingerprint

Castration
C-Reactive Protein
Albumins
Prostatic Neoplasms
docetaxel
Survival
Neoplasms
Therapeutics
ROC Curve
Androgens
Survival Rate

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Uchimoto, T., Komura, K., Fujiwara, Y., Saito, K., Tanda, N., Matsunaga, T., ... Azuma, H. (2020). Prognostic impact of C-reactive protein-albumin ratio for the lethality in castration-resistant prostate cancer. Medical Oncology, 37(1), [9]. https://doi.org/10.1007/s12032-019-1332-7
Uchimoto, Taizo ; Komura, Kazumasa ; Fujiwara, Yuya ; Saito, Kenkichi ; Tanda, Naoki ; Matsunaga, Tomohisa ; Ichihashi, Atsushi ; Tsutsumi, Takeshi ; Tsujino, Takuya ; Yoshikawa, Yuki ; Nishimoto, Yudai ; Takai, Tomoaki ; Minami, Koichiro ; Taniguchi, Kohei ; Tanaka, Tomohito ; Uehara, Hirofumi ; Hirano, Hajime ; Nomi, Hayahito ; Ibuki, Naokazu ; Takahara, Kiyoshi ; Inamoto, Teruo ; Azuma, Haruhito. / Prognostic impact of C-reactive protein-albumin ratio for the lethality in castration-resistant prostate cancer. In: Medical Oncology. 2020 ; Vol. 37, No. 1.
@article{9ef49e98a1ec4755b3e75c1937ad84e8,
title = "Prognostic impact of C-reactive protein-albumin ratio for the lethality in castration-resistant prostate cancer",
abstract = "This study aimed to assess the clinical value of C-reactive protein-albumin ratio (CAR) at the initiation of first-line treatment for castration-resistant prostate cancer (CRPC). We identified 221 CRPC patients treated with either androgen-signaling inhibitors (ASIs: abiraterone and enzalutamide) or docetaxel as the first-line treatment. The value of CAR was evaluated at the initiation of first-line treatment. The optimal cutoff value of CAR for the prediction of lethality was defined by the receiver operating characteristic curve and the Youden Index. The primary endpoints of the study included overall survival (OS) and cancer-specific survival (CSS). The median age was 74 years. The optimal cutoff value of CAR in newly diagnosed CRPC patients was 0.5 (CAR > 0.5: n = 77 and CAR ≤ 0.5: n = 144). The 3-year OS and CSS rate in patients with CAR > 0.5 were significantly lower than those with CAR ≤ 0.5 (OS: 30.9{\%} vs 55.5{\%}, p < 0.001) (CSS: 42.5{\%} vs 65.4{\%}, p < 0.001). A multivariate analysis consistently demonstrated that CAR was an independent predictor for both OS and CSS. When stratified by the first-line treatments, patients with CAR > 0.5 has significantly shorter CSS than those with CAR ≤ 0.5 in abiraterone (median of 23 vs 49 months, p < 0.001) and enzalutamide (median of 23 vs 41 months, p = 0.0016), whereas no difference was observed in patients treated with docetaxel as the first-line treatment (median of 34 and 37 months, p = 0.7708). Despite the limited cohort size and retrospective design, increased CAR seemed to serve as an independent predictor of OS and CSS for patients newly diagnosed with CRPC.",
author = "Taizo Uchimoto and Kazumasa Komura and Yuya Fujiwara and Kenkichi Saito and Naoki Tanda and Tomohisa Matsunaga and Atsushi Ichihashi and Takeshi Tsutsumi and Takuya Tsujino and Yuki Yoshikawa and Yudai Nishimoto and Tomoaki Takai and Koichiro Minami and Kohei Taniguchi and Tomohito Tanaka and Hirofumi Uehara and Hajime Hirano and Hayahito Nomi and Naokazu Ibuki and Kiyoshi Takahara and Teruo Inamoto and Haruhito Azuma",
year = "2020",
month = "1",
day = "1",
doi = "10.1007/s12032-019-1332-7",
language = "English",
volume = "37",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",
number = "1",

}

Uchimoto, T, Komura, K, Fujiwara, Y, Saito, K, Tanda, N, Matsunaga, T, Ichihashi, A, Tsutsumi, T, Tsujino, T, Yoshikawa, Y, Nishimoto, Y, Takai, T, Minami, K, Taniguchi, K, Tanaka, T, Uehara, H, Hirano, H, Nomi, H, Ibuki, N, Takahara, K, Inamoto, T & Azuma, H 2020, 'Prognostic impact of C-reactive protein-albumin ratio for the lethality in castration-resistant prostate cancer', Medical Oncology, vol. 37, no. 1, 9. https://doi.org/10.1007/s12032-019-1332-7

Prognostic impact of C-reactive protein-albumin ratio for the lethality in castration-resistant prostate cancer. / Uchimoto, Taizo; Komura, Kazumasa; Fujiwara, Yuya; Saito, Kenkichi; Tanda, Naoki; Matsunaga, Tomohisa; Ichihashi, Atsushi; Tsutsumi, Takeshi; Tsujino, Takuya; Yoshikawa, Yuki; Nishimoto, Yudai; Takai, Tomoaki; Minami, Koichiro; Taniguchi, Kohei; Tanaka, Tomohito; Uehara, Hirofumi; Hirano, Hajime; Nomi, Hayahito; Ibuki, Naokazu; Takahara, Kiyoshi; Inamoto, Teruo; Azuma, Haruhito.

In: Medical Oncology, Vol. 37, No. 1, 9, 01.01.2020.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prognostic impact of C-reactive protein-albumin ratio for the lethality in castration-resistant prostate cancer

AU - Uchimoto, Taizo

AU - Komura, Kazumasa

AU - Fujiwara, Yuya

AU - Saito, Kenkichi

AU - Tanda, Naoki

AU - Matsunaga, Tomohisa

AU - Ichihashi, Atsushi

AU - Tsutsumi, Takeshi

AU - Tsujino, Takuya

AU - Yoshikawa, Yuki

AU - Nishimoto, Yudai

AU - Takai, Tomoaki

AU - Minami, Koichiro

AU - Taniguchi, Kohei

AU - Tanaka, Tomohito

AU - Uehara, Hirofumi

AU - Hirano, Hajime

AU - Nomi, Hayahito

AU - Ibuki, Naokazu

AU - Takahara, Kiyoshi

AU - Inamoto, Teruo

AU - Azuma, Haruhito

PY - 2020/1/1

Y1 - 2020/1/1

N2 - This study aimed to assess the clinical value of C-reactive protein-albumin ratio (CAR) at the initiation of first-line treatment for castration-resistant prostate cancer (CRPC). We identified 221 CRPC patients treated with either androgen-signaling inhibitors (ASIs: abiraterone and enzalutamide) or docetaxel as the first-line treatment. The value of CAR was evaluated at the initiation of first-line treatment. The optimal cutoff value of CAR for the prediction of lethality was defined by the receiver operating characteristic curve and the Youden Index. The primary endpoints of the study included overall survival (OS) and cancer-specific survival (CSS). The median age was 74 years. The optimal cutoff value of CAR in newly diagnosed CRPC patients was 0.5 (CAR > 0.5: n = 77 and CAR ≤ 0.5: n = 144). The 3-year OS and CSS rate in patients with CAR > 0.5 were significantly lower than those with CAR ≤ 0.5 (OS: 30.9% vs 55.5%, p < 0.001) (CSS: 42.5% vs 65.4%, p < 0.001). A multivariate analysis consistently demonstrated that CAR was an independent predictor for both OS and CSS. When stratified by the first-line treatments, patients with CAR > 0.5 has significantly shorter CSS than those with CAR ≤ 0.5 in abiraterone (median of 23 vs 49 months, p < 0.001) and enzalutamide (median of 23 vs 41 months, p = 0.0016), whereas no difference was observed in patients treated with docetaxel as the first-line treatment (median of 34 and 37 months, p = 0.7708). Despite the limited cohort size and retrospective design, increased CAR seemed to serve as an independent predictor of OS and CSS for patients newly diagnosed with CRPC.

AB - This study aimed to assess the clinical value of C-reactive protein-albumin ratio (CAR) at the initiation of first-line treatment for castration-resistant prostate cancer (CRPC). We identified 221 CRPC patients treated with either androgen-signaling inhibitors (ASIs: abiraterone and enzalutamide) or docetaxel as the first-line treatment. The value of CAR was evaluated at the initiation of first-line treatment. The optimal cutoff value of CAR for the prediction of lethality was defined by the receiver operating characteristic curve and the Youden Index. The primary endpoints of the study included overall survival (OS) and cancer-specific survival (CSS). The median age was 74 years. The optimal cutoff value of CAR in newly diagnosed CRPC patients was 0.5 (CAR > 0.5: n = 77 and CAR ≤ 0.5: n = 144). The 3-year OS and CSS rate in patients with CAR > 0.5 were significantly lower than those with CAR ≤ 0.5 (OS: 30.9% vs 55.5%, p < 0.001) (CSS: 42.5% vs 65.4%, p < 0.001). A multivariate analysis consistently demonstrated that CAR was an independent predictor for both OS and CSS. When stratified by the first-line treatments, patients with CAR > 0.5 has significantly shorter CSS than those with CAR ≤ 0.5 in abiraterone (median of 23 vs 49 months, p < 0.001) and enzalutamide (median of 23 vs 41 months, p = 0.0016), whereas no difference was observed in patients treated with docetaxel as the first-line treatment (median of 34 and 37 months, p = 0.7708). Despite the limited cohort size and retrospective design, increased CAR seemed to serve as an independent predictor of OS and CSS for patients newly diagnosed with CRPC.

UR - http://www.scopus.com/inward/record.url?scp=85075376011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075376011&partnerID=8YFLogxK

U2 - 10.1007/s12032-019-1332-7

DO - 10.1007/s12032-019-1332-7

M3 - Article

C2 - 31754918

AN - SCOPUS:85075376011

VL - 37

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 1

M1 - 9

ER -